<DOC>
	<DOCNO>NCT00462956</DOCNO>
	<brief_summary>This study design evaluate efficacy safety GW572016 patient refractory breast cancer consist two cohort patient . Patients Cohort A must ErbB2 overexpressing tumor patient Cohort B must non-ErbB2 overexpressing tumor . Patients eligible study must advance metastatic breast cancer previously receive treatment anthracycline taxane .</brief_summary>
	<brief_title>GW572016 In Patients With Advanced Or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Confirmed advance ( IIIb Stage IV ) breast cancer progress prior anthracycline taxanes contain regimen + trastuzumab cohort A patient . Patients must adequate blood , liver , kidney function either fully active restrict perform strenuous activity . Female patient childbearing potential must willing abstain intercourse 2 week prior administration first dose study medication 28 day final dose study medication willing consistently correctly use acceptable method birth control . Patients certain heart problem .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>lapatinib</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>trastuzumab ( Herceptin )</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>ErbB2</keyword>
	<keyword>ErbB1</keyword>
</DOC>